A U.S. miliray helicopter hovering about 7 feet above the ground and several soldiers near it, one on a stretcher being carried by two to four soldiers

Imbed Biosciences Wins a $2M Award From the U.S. Army to Prevent Combat Wound Infections

Madison, WI — 10 November 2021 – Imbed Biosciences, Inc. announced today that it has been awarded a contract for $1,999,481 by the U.S. Army Medical Research and Development Command’s (USAMRDC) Military Infectious Diseases Research Program (MIDRP) to accelerate clinical development of an antibiofilm version of its next-generation Microlyte® Matrix wound dressing that can kill bacteria hidden in biofilms. The contract was awarded through Medical Technology Enterprise Consortium (MTEC) for prototype solutions that prevent combat wound infections following blast injuries and burns.

Combat wound infections are a major risk to warfighter survivability and can delay their return to active duty, posing a significant burden to the Army Health System. Research has shown that greater than 30% of all combat wounds become infected. That percentage is expected to rise in a prolonged field care environment.

This competitive award was made in response to a solicitation from the U.S. Army seeking prototype solutions that prevent warfighter wound infections close to the point of injury without requiring evacuation to higher roles of care, and that enable speedy return of warfighters to duty. The proposed solution will be part of a system to provide an adequate response to traumatic penetrating combat injuries.

“Combat wounds are contaminated with bacteria that start forming biofilms within hours of injury and can lead to failure of treatment, septic shock, and death”, said Ankit Agarwal, co-founder and CEO of the company. “An advanced version of our FDA-cleared Microlyte® Matrix wound dressing kills bacteria hidden in biofilms. The new matrix is ultrathin, bioresorbable, provides a template for cell growth, and can prevent biofilm infections in wounds for several days. This award will fund a prospective human clinical trial of the novel antibiofilm matrix on donor site wounds in patients in need of autologous skin grafts. We are honored to develop this advanced wound matrix for maximizing the readiness and performance of our warfighters in the field.”

About MIDRP:

USAMRDC’s MIDRP is one of the six major core research program areas that lead the planning and programming for Army and Defense Health Program research portfolios. As such, MIDRP oversees for DOD a world class requirements-driven infectious diseases Science and Technology program. More information at https://mrdc.amedd.army.mil.

About MTEC:

MTEC is a non-profit enterprise partnership in collaboration with industry and academia to facilitate biomedical research and development activities in cooperation with USAMRDC for U.S. military personnel’s health. For more information, visit mtec-sc.org.

Find this article at: https://www.businesswire.com/news/home/20211110005323/en/Imbed-Biosciences-Wins-a-2M-Award-From-the-U.S.-Army-to-Prevent-Combat-Wound-Infections

About Imbed Biosciences, Inc.

Imbed Biosciences Inc. is a privately held biotech company registered with the FDA as a medical device manufacturer with an ISO 13485 certified quality management system. The company has a portfolio of products in development based on its patented Microlyte® Matrix technology for tissue engineering to combat local pain and infections in complex wounds such as burns, chronic ulcers, surgical wounds, epidermolysis bullosa, and colorectal surgeries. Research programs at Imbed are partly funded by SBIR grants from National Institutes of Health (NIH).